Key Drivers
- Strong FCF
- High leverage
- Negative equity
AIAI Summary
DaVita's transition from a leveraged “cash‑machine” dialysis operator to a tech- and value‑based care platform means core FCF supports buybacks and investment, but the investment case now hinges on timely IKC/value‑based revenue realization and payer stability—monitor IKC revenue visibility, treatment-per-day trends, and leverage/interest-coverage metrics closely as they will determine upside versus rapid downside risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong FCF
- •High leverage
- •Negative equity
Strong cash-generative operations and mid-teens EBITDA margins underpin solid FCF and reasonable multiples, but extreme leverage (debt > market cap) and negative book equity are material solvency risks.
Price Behavior
Key Price Behavior Insights:
- •Near-term support
- •Failed breakout
- •Mild downside drift
Price is trading range-bound with a slight drift lower and sitting close to short-term support, so watch for a bounce around $148–$150 or a downside break if selling pressure resumes.
Modest decline from $150.73 to $149.31 over last month, indicating range-bound action
Sentiment & News
Key News Insights:
- •Earnings momentum
- •Institutional shifts
- •Value-based progress
DaVita's strong Q4, earnings-driven rally, upbeat value-based care progress and mixed but notable institutional buying have pushed the stock toward 52-week highs and renewed investor interest.
Continued execution on value-based care and solid earnings momentum should support upside, though mixed shareholder activity warrants monitoring for volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings